KPV Half-Life & Stability
Part of the full KPV guide - a melanocortin-derived c-terminal tripeptide reference compound, identity-verified with a COA on every vial.
In brief
KPV's pharmacokinetic and stability profile is best understood by separating what the provided data establish from what must be inferred from general peptide-class principles. The entry does not report a measured half-life, clearance rate, or degradation constant for KPV, so this spoke does not assign any such number; doing so would be fabrication. What the data do establish is structurally informative: KPV is a small tripeptide (Lys-Pro-Val, 342.43 g/mol, C16H30N4O4) and a substrate of the PepT1 oligopeptide transporter in the cited in-vitro models. From those facts, combined with general principles that apply broadly to short peptides, we can discuss expected handling and stability behavior in laboratory contexts while clearly flagging where peptide-specific measurements are absent. The framing throughout is in-vitro stability and storage behavior of research material, not human pharmacokinetics.
The detail
A closer look
01
What the data establish versus general principles
The provided entry gives no KPV-specific half-life, clearance, or in-vivo pharmacokinetic value, so none is stated here. The concrete, data-supported point relevant to disposition is that KPV is taken up intracellularly through the PepT1 transporter in the cited cell models, meaning its cellular fate is tied to a transporter-mediated route rather than passive receptor occupancy. Beyond that, general peptide-class principles apply: short, unmodified peptides are typically susceptible to peptidase activity in biological matrices, which tends to limit persistence. The presence of a proline residue in the Lys-Pro-Val sequence is a general structural feature often associated with altered susceptibility to certain peptidases, but the entry provides no measurement quantifying this for KPV, so it is noted only as a general sequence observation.
02
Stability and storage in laboratory handling
For laboratory stability, the operative principles are those of small lyophilized peptides generally. In dry, freeze-dried form, such peptides are typically more stable and are stored cold and sealed; once reconstituted, peptide solutions become more labile and are generally held refrigerated for short-term work and frozen for longer-term storage, with freeze-thaw cycling minimized. Bacteriostatic water's benzyl alcohol content supports a multi-withdrawal working window for reconstituted material. Because the entry supplies no measured shelf-life, degradation rate, or solution-stability window specific to KPV, any working stability limit should be determined empirically and recorded per laboratory protocol. These statements describe research-material handling and explicitly avoid any in-vivo or human pharmacokinetic claim, consistent with the in-vitro framing of all provided data.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. KPV is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.